GI Toxicities from Cancer Therapy

Podolski, Amanda J.; Gucalp, Rasim

doi:10.1007/978-3-030-30192-7_93

Amanda J. Podolski³ &
Rasim Gucalp³

185 Accesses

Abstract

Gastrointestinal toxicities including nausea, vomiting, oral mucositis, diarrhea, and constipation are common side effects of chemotherapy, targeted agents, and immunotherapy in cancer patients. The frequency and severity of these adverse effects vary based on the specific drugs/regimen, frequency, dosage, tumor type, and individual susceptibility. Combination of different cancer drugs and concurrent chemotherapy plus radiation therapy increases the risk and severity of GI toxicity. Many of these complications are life-threatening and require immediate attention and treatment. These toxicities may cause treatment delays, dose adjustment, and/or discontinuation of treatment, as well as a decrease in quality of life. Knowledge of the adverse effects seen with each agent is helpful to properly premedicate patients to prevent toxicities and to act in a timely manner to treat concerning symptoms when they arise. In this chapter, we will discuss GI toxicity of cytotoxic drugs, targeted therapies, and immunotherapies separately.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

Abdel-Rahman O, ElHalawani H, Ahmed H, Ellithy M. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2015;9(11):1433–45. https://doi.org/10.1586/17474124.2015.1087847.
Article CAS PubMed Google Scholar
Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, Wang Y. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother. 2019;68(4):553–61. https://doi.org/10.1007/s00262-019-02303-1.
Article CAS PubMed Google Scholar
Alessandrino F, Krajewski KM, Tirumani SH, Braschi-Amirfarzan M, Jagannathan JP, Ramaiya NH, Di Salvo DN. Biliary and pancreatic complications of molecular targeted therapies in cancer imaging. Abdom Radiol. 2017;42(6):1721–33. https://doi.org/10.1007/s00261-017-1050-6.
Article Google Scholar
Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, Awad MM. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol (NY). 2019;44(5):1917–27. https://doi.org/10.1007/s00261-019-01935-2.
Article Google Scholar
Ali AK, Watson DE. Pharmacovigilance assessment of immune-mediated reactions reported for checkpoint inhibitor cancer immunotherapies. Pharmacotherapy. 2017;37(11):1383–90. https://doi.org/10.1002/phar.2035.
Article CAS PubMed Google Scholar
Amaral T, Nouri N, Garbe C. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma. Expert Rev Anticancer Ther. 2016;16(7):705–15. https://doi.org/10.1080/14737140.2016.1192469.
Article CAS PubMed Google Scholar
Andrews P, Naylor R, Joss R. Neuropharmacology of emesis and its relevance to anti-emetic therapy. Support Care Cancer. 1998;6:197. https://doi.org/10.1007/s005200050154.
Article CAS PubMed Google Scholar
Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, Wedlake L, Bridgewater J, Glynne-Jones R, Allum W, Chau I, Wilson R, Ferry D. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):447–60. https://doi.org/10.1016/S1470-2045(14)70006-3.
Article Google Scholar
Borofsky SE, et al. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom Imaging. 2013;38(2):265.
Article PubMed Google Scholar
Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010;11(4):373–82. https://doi.org/10.1016/S1470-2045(09)70341-9.
Article CAS PubMed Google Scholar
Bouabdallah K, Ribrag V, Terriou L, Soria J-C, Delarue R. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr Opin Oncol. 2013;25:S1–S12. https://doi.org/10.1097/CCO.0b013e32835de8ee.
Article CAS PubMed Google Scholar
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, … National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–68. https://doi.org/10.1200/JCO.2017.77.6385.
Brown ZJ, Heinrich B, Steinberg SM, Yu SJ, Greten TF. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. J Immunother Cancer. 2017;5(1):93. https://doi.org/10.1186/s40425-017-0298-2.
Article PubMed PubMed Central Google Scholar
Cabezos PA, Vera G, Martín-fontelles MI, Fernández-pujol R, Abalo R. Cisplatin-induced gastrointestinal dysmotility is aggravated after chronic administration in the rat. Comparison with pica. Neurogastroenterol Motil. 2010;22(7):797–e225. https://doi.org/10.1111/j.1365-2982.2010.01483.x.
Article CAS PubMed Google Scholar
Cartoni C, Dragoni F, Micozzi A, Pescarmona E, Mecarocci S, Chirletti P, … Mandelli F. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol. 2001;19(3):756–61. https://doi.org/10.1200/jco.2001.19.3.756.
Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, … Pazdur R. FDA approval summary: ramucirumab for gastric cancer. Clin Cancer Res. 2015;21(15):3372–6. https://doi.org/10.1158/1078-0432.CCR-15-0600.
Chambers MS, Rugo HS, Litton JK, Meiller TF. Stomatitis associated with mammalian target of rapamycin inhibition: a review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc. 2018;149(4):291–8. https://doi.org/10.1016/j.adaj.2017.10.024.
Article PubMed Google Scholar
Chang M-L, Liaw Y-F. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61(6):1407–17. https://doi.org/10.1016/j.jhep.2014.08.033.
Article PubMed Google Scholar
Chang ST, Menias CO, Lubner MG, Mellnick VM, Hara AK, Desser TS. Molecular and clinical approach to intra-abdominal adverse effects of targeted cancer therapies. Radiographics. 2017;37(5):1461–82. https://doi.org/10.1148/rg.2017160162.
Article PubMed Google Scholar
Chen J, Pezhouh M, Lauwers G, Masia R. Histopathologic features of colitis due to immunotherapy with Anti-PD-1 antibodies. Am J Surg Pathol. 2017;41(5):643–54. https://doi.org/10.1097/PAS.0000000000000829.
Article PubMed Google Scholar
Chikarmane SA, Khurana B, Krajewski KM, Shinagare AB, Howard S, Sodickson A, … Ramaiya NJER. What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents. Emerg Radiol. 2012;19(6):535–46. https://doi.org/10.1007/s10140-012-1052-1.
Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, … Zelenetz AD. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779–86. https://doi.org/10.3109/10428194.2015.1022770.
Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep. 2017;19(1):3. https://doi.org/10.1007/s11894-017-0540-6.
Article PubMed Google Scholar
Crown JP, Burris HA, Boyle F, Jones S, Koehler M, Newstat BO, … Chan S. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2008;112(2):317–25. https://doi.org/10.1007/s10549-007-9860-9.
Cuneo A, Barosi G, Danesi R, Fagiuoli S, Ghia P, Marzano A, … Zinzani PL. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper. Hematol Oncol. 2019;37(1):3–14. https://doi.org/10.1002/hon.2540.
Davila M, Bresalier RS. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol. 2008;5:682. https://doi.org/10.1038/ncpgasthep1277.
Article PubMed Google Scholar
Denlinger CS, Barsevick AM. The challenges of colorectal cancer survivorship. J Natl Compr Cancer Netw. 2009;8:883.
Article Google Scholar
Diesendruck Y, et al. Novel immune check point inhibiting antibodies in cancer therapy – Opportunities and challenges. Drug Resist Updat. 2017;30:39–47.
Article PubMed Google Scholar
Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV, … Corrie PG. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017;2(4):e000268–8. https://doi.org/10.1136/esmoopen-2017-000268.
Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, … Zinzani PL Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–905. https://doi.org/10.1200/jco.2017.75.4648.
Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, … Testori A. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55. https://doi.org/10.1056/NEJMoa1611299.
Einhorn M, Davidsohn I. Hepatotoxicity of mercaptopurine. JAMA. 1964;188(9):802–6. https://doi.org/10.1001/jama.1964.03060350028007.
Article CAS PubMed Google Scholar
Elad S, et al. Oral complications of nonsurgical cancer therapies. Atlas Oral Maxillofac Surg Clin North Am. 2017;25(2):133–47.
Article PubMed Google Scholar
Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, … Stilgenbauer S. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446–55. https://doi.org/10.1182/blood-2018-05-850461.
Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review immune-related adverse effects of immune checkpoint inhibitors immune-related adverse effects of immune checkpoint inhibitors. JAMA Oncol. 2016;2(10):1346–53. https://doi.org/10.1001/jamaoncol.2016.1051.
Article PubMed Google Scholar
Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21(5):807–14. https://doi.org/10.1200/JCO.2003.08.058.
Article CAS PubMed Google Scholar
Ganapathi AM, et al. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. J Am Coll Surg. 2012;214(4):582.
Article PubMed Google Scholar
Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, … Ott PA. Diagnostic comparison of ct scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients. Cancer Immunol Res. 2017;5(4):286–91. https://doi.org/10.1158/2326-6066.CIR-16-0302
Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, … Haanen JBAG. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3(1):e000278. https://doi.org/10.1136/esmoopen-2017-000278.
Gonzalez SA, Perrillo RP. Hepatitis B virus reactivation in the setting of cancer chemotherapy and other immunosuppressive drug therapy. Clin Infect Dis. 2016;62(Suppl 4):S306–13. https://doi.org/10.1093/cid/ciw043.
Article CAS PubMed PubMed Central Google Scholar
Gorschlüter M, Mey U, Strehl J, Ziske C, Schepke M, Schmidt-Wolf IGH, … Glasmacher, A. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005;75(1):1–13. https://doi.org/10.1111/j.1600-0609.2005.00442.x.
Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, … Reiter A. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530–41. https://doi.org/10.1056/NEJMoa1513098.
Grabenbauer GG, Holger G. Management of radiation and chemotherapy related acute toxicity in gastrointestinal cancer. Best Pract Res Clin Gastroenterol. 2016;30(4):655–64. https://doi.org/10.1016/j.bpg.2016.06.001.
Article CAS PubMed Google Scholar
Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management. Am Soc Clin Oncol Educ Book. 2018;38:13–9. https://doi.org/10.1200/edbk_100013.
Article PubMed Google Scholar
Grunberg SM, Osoba D, Hesketh PJ. Support care cancer. 2005;13:80. https://doi.org/10.1007/s00520-004-0718-y.
Article PubMed Google Scholar
Harris DJ. Cancer treatment-induced mucositis pain: strategies for assessment and management. Ther Clin Risk Manag. 2006;2(3):251–8.
Article PubMed PubMed Central Google Scholar
Helissey C, Vicier C, Champiat S. The development of immunotherapy in older adults: new treatments, new toxicities? J Geriatr Oncol. 2016;7(5):325–33. https://doi.org/10.1016/j.jgo.2016.05.007.
Article PubMed Google Scholar
Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH. Taxanes: a new class of antitumor agents. Cancer Investig. 1995;13(4):381.
Article CAS Google Scholar
Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, … Artz AS. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Oncol Pract. 2015;33(19):2212–20. https://doi.org/10.1200/jco.2015.61.3745.
Innocenti M, Moscatelli G, Lopez S. Efficacy of Gelclair in reducing pain in palliative care patients with oral lesion: preliminary findings from an open pilot study. J Pain Symptom Manag. 2002;24:456–7.
Article CAS Google Scholar
Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity. Phamacogenomics J. 2002;2(1):43–7.
Article CAS Google Scholar
Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15:273. https://doi.org/10.1038/nrclinonc.2018.28.
Article CAS PubMed Google Scholar
Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol. 2019;15(3):231–44. https://doi.org/10.1080/17425255.2019.1574744.
Article CAS PubMed Google Scholar
Johnson DB, Balko JM. Biomarkers for immunotherapy toxicity: are cytokines the answer? Clin Cancer Res. 2019;25(5):1452–4. https://doi.org/10.1158/1078-0432.CCR-18-3858.
Article CAS PubMed Google Scholar
Jurczak W, Długosz-Danecka M, Wang M. Acalabrutinib for adults with mantle cell lymphoma. Expert Rev Clin Pharmacol. 2019;12(3):179–87. https://doi.org/10.1080/17512433.2019.1568868.
Article CAS PubMed Google Scholar
Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective. J Clin Pathol. 2018;71(8):665–71. https://doi.org/10.1136/jclinpath-2018-205143.
Article CAS PubMed Google Scholar
Kassem L, Shohdy KS, Lasheen S, Abdel-Rahman O, Ali A, Abdel-Malek RR. Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review. Crit Rev Oncol Hematol. 2019;134:56–64. https://doi.org/10.1016/j.critrevonc.2018.11.004.
Article PubMed Google Scholar
Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, … Nakagawa K. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investig New Drugs. 2017;35(4):529–36. https://doi.org/10.1007/s10637-017-0453-0.
Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, Ibrahim N. Ipilimumab-associated colitis: CT findings. Am J Roentgenol. 2013a;200(5):W468–74. https://doi.org/10.2214/AJR.12.9751.
Article Google Scholar
Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, Ibrahim N. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Investig New Drugs. 2013b;31(4):1071–7. https://doi.org/10.1007/s10637-013-9939-6.
Article CAS Google Scholar
Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29(04):364–72. https://doi.org/10.1055/s-0029-1240005.
Article PubMed Google Scholar
Kozloff MF, Yood MU, Berlin JD, Flynn PJ, Kabbinavar FF, Purdie DM, … Grothey AF. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14(9):862–70. https://doi.org/10.1634/theoncologist.2009-0071.
Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31–9. https://doi.org/10.1007/s40257-018-0384-3.
Article PubMed PubMed Central Google Scholar
Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM. Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging Res. 2017;44(Suppl 1):41–54.
Article CAS Google Scholar
Logan RM, Gibson RJ, Bowen JM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62:33–41. https://doi.org/10.1007/s00280-007-0570-0.
Article CAS PubMed Google Scholar
Lugowska I, Koseła-Paterczyk H, Kozak K, Rutkowski P. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 2015;8:2251–9. https://doi.org/10.2147/OTT.S72951.
Article CAS PubMed PubMed Central Google Scholar
Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, … Wong R. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol (Toronto, Ont). 2007;14(1):13–20.
Google Scholar
McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III, Fuchs CS. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002;94(15):1160–7. https://doi.org/10.1093/jnci/94.15.1160.
Article CAS PubMed Google Scholar
McQuade RM, Bornstein JC, Nurgali K. Anti-colorectal cancer chemotherapy-induced Diarrhoea: current treatments and side-effects. Int J Clin Med. 2014;5:44733.
Article Google Scholar
McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:414. https://doi.org/10.3389/fphar.2016.00414.
Article CAS PubMed PubMed Central Google Scholar
Mearns ES, Bell JA, Galaznik A, Puglielli SM, Cichewicz AB, Boulanger T, Garcia-Ribas I. Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review. Melanoma Manag. 2018;5(1):MMT01. https://doi.org/10.2217/mmt-2017-0027.
Article PubMed PubMed Central Google Scholar
Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, … Fuchs CS. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage ii and iii rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22(4):648–57. https://doi.org/10.1200/jco.2004.07.121.
Michot JM, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48.
Article CAS PubMed Google Scholar
Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol. 2006;33(1):106–20. https://doi.org/10.1053/j.seminoncol.2005.12.001.
Article CAS PubMed Google Scholar
Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J. The toxicity of busulphan and cyclophosphamide as the preparative regimen for. Bone Marrow Transplant. 1991;77(4):529–34. https://doi.org/10.1111/j.1365-2141.1991.tb08621.x.
Article CAS Google Scholar
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, … Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–24. https://doi.org/10.1001/jama.295.21.2516.
Nadeau BA, Fecher LA, Owens SR, Razumilava N. Liver toxicity with Cancer checkpoint inhibitor therapy. Semin Liver Dis. 2018;38(4):366. https://doi.org/10.1055/s-0038-1667358.
Article CAS PubMed Google Scholar
Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, … Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–91. https://doi.org/10.1093/annonc/mdv383.
Nesher L, Rolston KVI. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis. 2012;56(5):711–7. https://doi.org/10.1093/cid/cis998.
Article PubMed Google Scholar
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. https://doi.org/10.1038/nrc3239.
Article CAS PubMed PubMed Central Google Scholar
Parlati L, Vallet-Pichard A, Batista R, Hernvann A, Sogni P, Pol S, Mallet V. Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study. J Hepatol. 2018;69(6):1396–7. https://doi.org/10.1016/j.jhep.2018.08.014.
Article PubMed Google Scholar
Patil PD, Burotto M, Velcheti V. Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. Expert Rev Mol Diagn. 2018;18(3):297–305. https://doi.org/10.1080/14737159.2018.1440209.
Article CAS PubMed Google Scholar
Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56–63. https://doi.org/10.1016/j.critrevonc.2019.02.001.
Article PubMed Google Scholar
Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. J Pancreas. 2010;11(3):291–3.
Google Scholar
Phipps C, Chen Y, Tan D. Lymphoproliferative disease and hepatitis B reactivation: challenges in the era of rapidly evolving targeted therapy. Clin Lymphoma Myeloma Leuk. 2016;16(1):5–11. https://doi.org/10.1016/j.clml.2015.11.009.
Article PubMed Google Scholar
Pico J-L, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist. 1998;3(6):446–51.
Article CAS PubMed Google Scholar
Pini A, Garella R, Idrizaj E, Calosi L, Baccari MC, Vannucchi MG. Glucagon-like peptide 2 counteracts the mucosal damage and the neuropathy induced by chronic treatment with cisplatin in the mouse gastric fundus. Neurogastroenterol Motil. 2016;28(2):206–16. https://doi.org/10.1111/nmo.12712.
Article CAS PubMed Google Scholar
Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, … on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. https://doi.org/10.1186/s40425-017-0300-z.
Rhodes J, Mato A, Sharman JP. Monitoring and management of toxicities of novel b cell signaling agents. Curr Oncol Rep. 2018;20(6):49. https://doi.org/10.1007/s11912-018-0694-x.
Article CAS PubMed Google Scholar
Riley P, McCabe MG, Glenny A-M. Oral cryotherapy for preventing oral mucositis in patients receiving cancer treatment. JAMA Oncol. 2016;2(10):1365–6. https://doi.org/10.1001/jamaoncol.2016.2680.
Article PubMed Google Scholar
Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, … Litton JK. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18(5):654–62. https://doi.org/10.1016/S1470-2045(17)30109-2.
Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, … Treatment. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat. 2019;175(1):5–15. https://doi.org/10.1007/s10549-018-05102-x.
Scott LJ. Larotrectinib: first global approval. Drugs. 2019;79(2):201–6. https://doi.org/10.1007/s40265-018-1044-x.
Article CAS PubMed Google Scholar
Shafi MA, Bresalier RS. The gastrointestinal complications of oncologic therapy. Gastroenterol Clin N Am. 2010;39(3):629–47. https://doi.org/10.1016/j.gtc.2010.08.004.
Article Google Scholar
Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 2019;42(2):181–98. https://doi.org/10.1007/s40264-018-0772-x.
Article CAS PubMed Google Scholar
Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491–503. https://doi.org/10.1007/s40264-013-0048-4.
Article CAS PubMed Google Scholar
Shahid F, Farooqui Z, Khan F. Cisplatin-induced gastrointestinal toxicity: an update on possible mechanisms and on available gastroprotective strategies. Eur J Pharmacol. 2018;827:49–57. https://doi.org/10.1016/j.ejphar.2018.03.009.
Article CAS PubMed Google Scholar
Siakavellas S, Bamias G. Checkpoint inhibitor colitis: a new model of inflammatory bowel disease? Curr Opin Gastroentrol. 2018;34(6):377–83. https://doi.org/10.1097/MOG.0000000000000482.
Article CAS Google Scholar
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, … Shaw AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–67. https://doi.org/10.1016/S1470-2045(18)30649-1.
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. https://doi.org/10.1016/j.ctrv.2016.02.001.
Article CAS PubMed Google Scholar
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, … Emmanouilides C. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351(25):2590–8. https://doi.org/10.1056/NEJMoa040125.
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63. https://doi.org/10.1177/1758834009355164.
Article CAS PubMed PubMed Central Google Scholar
Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298–307. https://doi.org/10.1182/blood-2018-11-846808.
Article CAS PubMed PubMed Central Google Scholar
Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297:630–4.
Article CAS PubMed Google Scholar
Su Q, Zhang X-C, Zhang C-G, Hou Y-L, Yao Y-X, Cao B-W. Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis. J Immunol Res. 2018;2018:1027323. https://doi.org/10.1155/2018/1027323.
Article CAS PubMed PubMed Central Google Scholar
Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, … Baselga J. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2017;28(4):761–8. https://doi.org/10.1093/annonc/mdw695.
Tao Z, Li SX, Shen K, Zhao Y, Zeng H, Ma X. Safety and efficacy profile of neratinib: a systematic review and meta-analysis of 23 prospective clinical trials. Clin Drug Investig. 2019;39(1):27–43. https://doi.org/10.1007/s40261-018-0719-0.
Article CAS PubMed Google Scholar
Thompson PA, Burger JA. Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018;27(1):31–42. https://doi.org/10.1080/13543784.2018.1404027.
Article CAS PubMed Google Scholar
Thompson JA, Schneider BJ, Brahmer JR, Andrews S, Armand P, Bhatia S, … Scavone JL. Management of immunotherapy-related toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019;17(3):255–89. https://doi.org/10.6004/jnccn.2019.0013
Thomsen M, Vitetta L. Adjunctive treatments for the prevention of chemotherapy- and radiotherapy-induced mucositis. Integr Cancer Ther. 2018;17(4):1027–47. https://doi.org/10.1177/1534735418794885.
Article PubMed PubMed Central Google Scholar
Tirumani SH, Jagannathan JP, Shinagare AB, Kim K w, Krajewski KM, Ramaiya NH. Acute pancreatitis associated with molecular targeted therapies: a retrospective review of the clinico-radiological features, management and outcome. Pancreatology. 2013;13(5):461–7. https://doi.org/10.1016/j.pan.2013.08.001.
Article CAS PubMed Google Scholar
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, … Hodi FS. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30. https://doi.org/10.1200/JCO.2013.53.0105.
Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol. 2013;5(11):612–20. https://doi.org/10.4254/wjh.v5.i11.612.
Article PubMed PubMed Central Google Scholar
Urbach DR, Rotstein OD. Typhlitis. Can J Surg/J canadien chirurgie. 1999;42(6):415–9.
CAS Google Scholar
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, … on behalf of the First BEAT Investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20(11):1842–1847. https://doi.org/10.1093/annonc/mdp233.
Van Sebille YZA, Gibson RJ, Wardill HR, Bowen JM. ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis. Cancer Treat Rev. 2015;41(7):646–52. https://doi.org/10.1016/j.ctrv.2015.05.011.
Article CAS PubMed Google Scholar
Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, … de Boer NK. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14(6):836–42. https://doi.org/10.1016/j.cgh.2015.12.028.
Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25(5):1713–39. https://doi.org/10.1007/s00520-017-3629-4.
Article PubMed Google Scholar
Viswanathan C. Imaging of chemotherapy-related iatrogenic abdominal and pelvic conditions. Radiol Clin N Am. 2014;52(5):1029–40.
Article PubMed Google Scholar
Viswanathan C, Bhosale P, Ganeshan DM, Truong MT, Silverman P, Balachandran A. Imaging of complications of oncological therapy in the gastrointestinal system. Cancer Imaging. 2012;12(1):163–72. https://doi.org/10.1102/1470-7330.2012.0014.
Article PubMed PubMed Central Google Scholar
Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer. 2017;141(5):1018–28. https://doi.org/10.1002/ijc.30678.
Article CAS PubMed Google Scholar
Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, … Johnson DB. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysisfatal toxic effects associated with immune checkpoint inhibitors fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol. 2018;4(12):1721–8.https://doi.org/10.1001/jamaoncol.2018.3923.
Wardill HR, Bowen JM, Al-Dasooqi N, Sultani M, Bateman E, Stansborough R, … Gibson RJ. Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer Biol Ther. 2014;15(2):236–44. https://doi.org/10.4161/cbt.27222.
Watters AL, et al. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011;47(6):441–8. ISSN 1368-8375
Article CAS PubMed Google Scholar
Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep. 2017;5(11):59. https://doi.org/10.1007/s40134-017-0256-2.
Article PubMed Central Google Scholar
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, … Hurria A. (2014). International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603. https://doi.org/10.1200/JCO.2013.54.8347.
Yang JC-H, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, … Cohen EEW. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):729–36. https://doi.org/10.1586/era.13.31.
Yuan A, Kurtz SL, Barysauskas CM, Pilotte AP, Wagner AJ, Treister NS. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. Oral Oncol. 2015;51(11):1026–33. https://doi.org/10.1016/j.oraloncology.2015.09.003.
Article CAS PubMed Google Scholar
Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer. 1998;34(12):1871–5. https://doi.org/10.1016/S0959-8049(98)00259-7.
Article CAS PubMed Google Scholar
Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31(6):965–73. https://doi.org/10.1038/s41379-018-0013-y.
Article PubMed Google Scholar

Download references

Author information

Authors and Affiliations

Department of Medical Oncology, Montefiore Medical Center, Bronx, NY, USA
Amanda J. Podolski & Rasim Gucalp

Authors

Amanda J. Podolski
View author publications
You can also search for this author in PubMed Google Scholar
Rasim Gucalp
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rasim Gucalp .

Editor information

Editors and Affiliations

Department of Medicine, Robert Wood Johnson School of Medicine, Rutgers University, New Brunswick, NJ, USA
C. S. Pitchumoni
Department of Medicine, Division of Geriatrics, Montefiore Medical Center, Wakefield Campus, Bronx, NY, USA
T.S. Dharmarajan

Rights and permissions

Reprints and permissions

Copyright information

About this entry

Cite this entry

Podolski, A.J., Gucalp, R. (2021). GI Toxicities from Cancer Therapy. In: Pitchumoni, C.S., Dharmarajan, T. (eds) Geriatric Gastroenterology. Springer, Cham. https://doi.org/10.1007/978-3-030-30192-7_93

Download citation

DOI: https://doi.org/10.1007/978-3-030-30192-7_93
Published: 04 September 2021
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-30191-0
Online ISBN: 978-3-030-30192-7
eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics